

PRVPATENT- OCH REGISTRERINGSVERKET
Patentavdelningen**Intyg
Certificate**

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.



(71) Sökande Astra Tech AB, Mölndal SE
Applicant (s)

(21) Patentansökningsnummer 0301974-2
Patent application number

(86) Ingivningsdatum 2003-07-03
Date of filing

Stockholm, 2004-06-11

För Patent- och registreringsverket
For the Patent- and Registration Office

Marita Öun
Marita Öun

Avgift
Fee

REC'D 21 JUN 2004

WIPO PCT

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

**PATENT- OCH
REGISTRERINGSVERKET
SWEDEN**

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

Original Copy

AWAPATENT AB

Kontor/Handläggare

Göteborg/Marie-Louise Jardle/MLA

ASTRA TECH AB

Ansökningsnr

Huvudfaxen Kassen

Vår referens

SE-21003514

1

A DEVICE FOR PROMOTING REGENERATION OF AN INJURED NERVE,
A KIT AND A BIODEGRADABLE SHEET FOR PREPARING SUCH A
DEVICE

Technical field

The present invention relates to the field of nerve regeneration. More specifically, the invention relates to a device for promoting regeneration of an injured nerve, a kit for preparing such a device, and a biodegradable sheet for preparing such a device. The invention also relates to the use of biodegradable guiding means for promoting regeneration of an injured nerve, and a method for promoting regeneration of an injured nerve.

10 Technical background

The anatomic nervous system consists of the central nervous system (CNS) and the peripheral nervous system (PNS), and comprises nerve cells, which are supported and protected by glial cells, such as Schwann cells.

15 A nerve cell (neuron) comprises a nerve cell body, from which dendrites and an axon extend. Axons are termed nerve fibres, and a nerve is a bundle of several nerve fibers.

20 Chemical stimulation of a neuron generates a nerve impulse that can pass between two or several neurons and the junction between two separate neurons is called a synapse.

25 The CNS consists of the brain and the spinal cord. Nerve cell bodies in the CNS are known as grey matter. So-called white matter in the CNS consists primarily of axons coated with a light-coloured supporting and insulating myelin sheet produced by glial cells.

30 Spinal nerves extend from the spinal cord and cranial nerves extend from the brainstem. The axons of these nerves transmit signals between the CNS and the rest of the body, and constitute the PNS. A cluster of nerve cell

2003 -07- 0 3

Huvudfaxen Kasser

2

bodies on a peripheral nerve is called a ganglion. Thus, nerve cell bodies are located in the brain, in the spinal cord, and in peripheral ganglia.

5 The axons in the PNS is either non-myelinated or myelinated. The nerve signal transmission is faster in myelinated nerve fibres. The insulating and supporting myelin sheet surrounding peripheral nerve fibres is produced by so-called Schwann cells.

10 Schwann cells also produce neurotrophic factors (nerve growth promoting substances) essential for nerve cell growth and function.

When a nerve is injured, a gap is formed whereby proximal and distal nerve portions are located at the gap. To bridge the gap and substantially re-establish
15 nerve function, axons in the proximal end of the injured nerve must navigate to reach the corresponding distal end of the injured nerve. Injury to an axon stimulates production of neurotrophic factors, which promote growth of the proximal nerve end. The proximal end of the injured
20 nerve also senses signals from other cells in the surroundings and determine the rate and direction of nerve growth.

After a lag period of approximately two weeks, during which the nerve growth is paralysed, the repair processes of the injured nerve start. Each myelinated axon of
25 the injured nerve divides into a multiplicity of fine regenerating axon sprouts with finger-like extensions which grow out from the proximal nerve end. The growth rate is generally 1-2 mm/day. When these sprouts reaches the distal end and contact has been established between the two
30 nerve ends, the Schwann cells are stimulated to proliferate and form a basal lamina of collagen, proteoglycans, and laminin. Moreover, regeneration of a larger number of axons is initiated, i.e. the quantity of axons is increased.
35

The sprouts extending from the proximal nerve end typically grow in many directions and unless the gap is

7003 -07- 0 3

Huvudfaxen Kallan

3

small, the axon sprouts from the proximal end may never establish contact with the corresponding distal end, thus resulting in permanent loss of nerve function.

Moreover, soft tissue damage, scar tissue formation
5 and disruption of blood supply may interrupt the natural nerve regeneration process.

Nerve defects have traditionally been reconstructed either by directly suturing together the ends of the split nerve or by surgical transfer of a part of a
10 healthy nerve from an uninjured location to the injured site. The healthy nerve is in the vast majority of cases taken from the patient (autograft) and only rarely is the nerve graft taken from a donor (allograft). These procedures are all difficult, expensive and not always suc-
15 cessful.

Another approach for nerve regeneration is the use of a nerve conduit (also referred to as nerve tube, nerve channel, nerve guide, tubular nerve prosthesis, etc).

The material constituting the nerve conduit should
20 preferably be biocompatible, biodegradable, non-toxic, non-carcinogenic, non-antigenic and should exhibit desirable mechanical properties, such as strength, flexibility, elasticity, and processibility. Furthermore, the material should preferably be porous to allow passage of
25 substances essential for nerve cell metabolism, such as water, salts, nutrients, etc. It may be noted that these considerations also apply to the invention.

Both inert biocompatible tubes, such as conduits of silicone, polyethylene, poly(vinyl chloride), poly(tetra-
30 fluorethylene), and biocompatible biodegradable conduits, such as conduits made of poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), hyaluronic acid, collagen, gelatine, or biological tissue, have been suggested for this purpose.

35 Preferably, the conduit is arranged such as the ends of the injured nerve will be located inside the lumen of the nerve conduit and by leaving a small gap between the

+46 31630263

Ink. t. Patent- och reg.verket

2003 -07- 0 3

Huvudfaxen Kassar

4

nerve ends, the conduit optimises the growth of the axon sprouts from the proximal nerve end in the proper direction towards the distal nerve end lead by endogenous neurotrophic guidance. Furthermore, the nerve conduit provides support to the fragile growing nerve and increases the local concentration of endogenous neurotrophic factors released around the growing nerve.

The use of a nerve conduit generally results in an increase in the number and/or size of regenerated axons and a decrease in the time required for regeneration as compared to natural nerve regeneration without the use of a nerve conduit.

To further promote nerve regeneration, it has been suggested, for instance in WO 97/37002, to add nerve growth promoting substances, such as nerve growth factor (NGF); brain-derived neurotrophic factor (BDNF); neurotrophin-3 (NT-3; neurotrophin-4 (NT-4); glial growth factor (GGF); insulin-like growth factor (IGF), including a variant of IGF called mechano-growth factor (MGF); platelet-derived growth factor (PDGF); fibroblast growth factor (FGF); transforming growth factor (TGF); epidermal growth factor (EGF); fibronectin; fibrin; laminin; cells, such as Schwann cells, stem cells and precursor cells thereof, endothelial cells, and fibroblasts; nutrients; nerve tissue extract, and/or other biologically active substances or cells, at the place of injury, such as within the lumen of the conduit.

Matrix materials, such as hydrogels, e.g. poly(ethylene oxide), hyaluronate, collagen, agarose, chitosan, methylcellulose, or alginate, comprised within the lumen of the nerve conduit have also been suggested, for instance in WO 97/37002, to promote the nerve regeneration, especially for regeneration of larger nerve gaps within the range of from 1 cm to 10 cm. It has also been suggested to disperse nerve growth promoting substances or cells in the matrix material.

Mechanical nerve guide structures (orientation aids) on the interior wall surface of the nerve conduit or in the lumen of the nerve conduit have also been suggested.

WO 01/81552 describes a patterned interior wall surface having nerve guiding grooves.

WO 88/06871 describes a nerve conduit having a plurality of guide channels in the lumen. The channels may, for instance, be defined between and/or through a plurality of longitudinally extending fibres, i.e. solid compact fibres or hollow fibres.

Also WO 97/37002 discloses mechanical guide means for guided tissue regeneration, e.g. in the form of fibres.

EP 1 201 256 describes a microporous guide tube of polymers of hydroxycarboxylic acids, optionally having several monofilaments of polymers of hydroxycarboxylic acids located in the guide tube, wherein the resorbability of the guide tube and the fibres decrease over their lengths. It is stated that the regenerated nerve should be exposed as early as possible so as to permit a normal metabolism with the environment. The guide tube and the fibres are thus more rapidly degraded at the proximal nerve end than at the distal nerve end. This is, for instance, obtained via the use of polymers having different molecular weights. The in vivo degradation time is stated to be from 0.5 to 6 months along the length of the tube and fibres.

Nevertheless, even though the time period required for establishing contact between the nerve ends is decreased using a nerve conduit having guiding means, such as fibres, within the lumen, it takes rather long time until the entire nerve has been regenerated to a satisfactory degree or, in some cases, a satisfactory nerve function is never attained.

Summary of the invention

The inventors have found that the use of guiding means, such as fibres, within the lumen of the nerve tube

2003 -07- 0 3

Huvudfaxen Kasse

6

generally increases the rate of nerve regeneration, but often provide a rather low quantity of regenerated axons, i.e. a quantity insufficient to establish a satisfactory nerve function. Thus, the inventors have found that it
5 would be a great advantage to obtain a higher quantity of regenerated axons, while maintaining a relatively high rate of nerve regeneration.

An object of the present invention is to alleviate the above problems and to improve the regeneration of in-
10 jured nerves, in particular to increase the quantity of regenerated axons and thereby enhance the chance of obtaining a satisfactory degree of retrieved nerve function. More specifically, an object of the invention is to increase the rate of axon density growth.

15 According to a first aspect of the invention, this object is achieved with a device for promoting regeneration of an injured nerve comprising a nerve encasement structure and a plurality of biodegradable guiding means, preferably a plurality of guiding fibres, wherein at
20 least a majority of the guiding means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_0 required for establishing regenerated contact between the ends of an injured nerve using the device for said regeneration.

25 The nerve encasement structure is preferably biodegradable, and more preferably at least a major part of the nerve encasement structure presents an in vivo degradation time t_2 being longer than t_1 ($t_2 > t_1$).

30 According to a second aspect of the invention, a device for promoting regeneration of an injured nerve is provided, said device comprising a biodegradable nerve encasement structure, and a plurality of biodegradable guiding means, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 , at least a
35 major part of the nerve encasement structure presents an in vivo degradation time t_2 , and t_2 being longer than t_1 ($t_2 > t_1$).

2003-07-03

Huvudföreläsning

7

Without being bound by any theory, it is believed that the guiding means, such as a plurality of fibres, initially should act as orientation aids for the axon sprouts until the regeneration process has established contact between the ends of the injured nerve (referred to as regenerated contact), i.e. until the axon sprouts extending from the proximal nerve end have established contact with the distal nerve end. Thereafter, the regenerated axons formed from the sprouts act as natural orientation aids for the succeeding growing axons and the guiding means are no longer required. It is believed that guiding means, such as fibres, will restrict or even block the growth of the succeeding growing axons and impair the amount of regenerated axons. Thus, according to the invention, the nerve guiding means, such as guiding fibres, should preferably be essentially disintegrated, more preferably completely degraded, when the regeneration process has established contact between the ends of the injured nerve.

When a nerve is injured, the nerve is paralysed for a period of about two weeks, said period being independent of the size of the gap. Thereafter the axons sprouts start to grow. The axon growth rate is generally about 1 mm/day, but the rate may vary within the range of from about 0.5 to about 2 mm/day.

Thus, a nerve gap of 1 cm is normally, when using a nerve conduit, bridged in about 19-34 days from the date of injury. The nerve then grows thicker by regeneration of more axons and myelination which takes about the same time as the bridging process, i.e. about 5-20 days for a 1 cm gap. Thus, the overall nerve regeneration process for a 1 cm gap would normally take approximately 1-2 months from the date of injury.

According to the invention, the guiding means, such as fibres, should preferably be essentially disintegrated, more preferably completely degraded, when the nerve gap has been bridged, i.e. when the regeneration

+46 31630263

Ink. t. Patent- och reg.verket

2003 -07- 0 3

8

Huvudföreläsningen

process has established contact between the ends of the injured nerve. The nerve encasement structure should advantageously support the fragile growing nerve even after contact has been established between the nerve ends and

5 said supporting structure should preferably last at least until the entire nerve regeneration process has been completed. The use of a porous nerve encasement structure has not been shown to negatively affect the regenerated nerve, so the structure may still be present a while after

10 the nerve has been essentially regenerated and a satisfactory nerve function has been attained.

According to a third aspect of the invention, a kit for preparing a device for promoting regeneration of an injured nerve is provided, said kit comprising a sheet

15 and a plurality of biodegradable guiding means, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_0 required for establishing regenerated contact between the ends of an injured nerve using the

20 device for said regeneration.

The sheet is preferably biodegradable, and more preferably at least a major part of the nerve encasement structure presents an in vivo degradation time t_2 being longer than t_1 ($t_2 > t_1$).

25 According to a fourth aspect of the invention a kit for preparing a device for promoting regeneration of an injured nerve is provided, said kit comprising a biodegradable sheet and a plurality of biodegradable guiding means, wherein at least a majority of the guiding means

30 presents an in vivo degradation time t_1 , at least a major part of the sheet presents an in vivo degradation time t_2 , and t_2 being longer than t_1 ($t_2 > t_1$).

35 According to a fifth aspect of the invention, a biodegradable sheet for preparing a device for promoting regeneration of an injured nerve is provided, said sheet having at least one surface at least partly coated with a dehydrated hydrogel material and a plurality of biode-

gradable guiding means, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_c required for establishing regenerated contact between the ends of an injured nerve using the device for said regeneration.

According to a sixth aspect of the invention, a biodegradable sheet for preparing a device for promoting regeneration of an injured nerve is provided, said sheet having at least one surface at least partly coated with a dehydrated hydrogel material and a plurality of biodegradable guiding means, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 , at least a major part of the sheet presents an in vivo degradation time t_2 , and t_2 being longer than t_1 ($t_2 > t_1$).

A seventh aspect of the invention relates to the use of a plurality of biodegradable guiding means for promoting regeneration of an injured nerve, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_c required for establishing regenerated contact between the ends of an injured nerve using the guiding means for said regeneration.

An eighth aspect of the invention relates to a method for promoting regeneration of an injured nerve, said method comprising the step of applying at said injured nerve a device according to the invention.

Other features and advantages of the present invention will become apparent from the following description of the invention.

Brief description of drawings

Fig 1 schematically shows an embodiment of the device according to the invention.

Detailed description of the invention

As used herein the term "degradation" of a material means cleavage of molecular chains, such as polymer

+46 31630263

Ink. t. Patent- och reg.verket

2003 -07- 0 3

Muvudföreläsn. Kassen

10

chains, constituting the material, thus reducing the molecular weight of the molecule. Degradation finally results in essentially complete mass loss. When the molecular weight of the molecule, e.g. a polymer, reaches the threshold level of water solubility of the breakdown products, rapid mass loss is observed, and the material is referred to as completely degraded.

As used herein the term "biodegradation" means degradation of a material (referred to as biodegradable material) over time by enzymatic action, by hydrolytic (non-enzymatic) action, and/or by other similar mechanisms in the human body. As used herein "biodegradation" also includes dissolution of a material in body fluids without any molecular chain cleavage or molecular mass decrease and subsequent removal of the dissolved material by cellular activity. Thus, as used herein biodegradable materials also include materials that are generally referred to as bioabsorbable materials.

It shall be noted that as used herein, biodegradable materials include both completely and partly biodegradable (including bioabsorbable) materials. However, it shall be noted that when referring to the invention, the biodegradable material is preferably a completely biodegradable material.

As used herein the term "in vivo degradation time" means the time period from implantation of a biodegradable material in a mammal, including a human, and degradation until the molecular weight of the material has been reduced to such a level that an essentially disintegrated material has been attained, or alternatively, dissolution of a bioabsorbable material until an essentially disintegrated material has been attained.

As used herein, an essentially disintegrated material means a material that provides no substantial axon growth guiding function and no substantial axon growth blocking effect in vivo.

As used herein the term "biocompatible" means that a material, when implanted in a host, does not provoke a foreign body reaction from the host.

5 As used herein the term "bioresorbable" means biodegradation of a material and subsequent elimination of the degradation products through natural pathways.

As used herein the term "fibre" means a cylindrical or tubular structure wherein the length is much larger than its cross-sectional dimension. The fibres can either
10 be solid or hollow.

As used herein the term "non-woven" means a type of fabric made directly from fibres or from a web of fibres without the preliminary yarn preparation needed for weaving or knitting. Non-woven may be compressed or non-
15 compressed.

As used herein the term "porous" means a sufficiently open structure that allows for passage of physiological fluids, substances, and/or cells.

As used herein "one day" means 24 hours.

20 The first device according to the invention for promoting regeneration of an injured nerve comprises a nerve encasement structure and a plurality of biodegradable guiding means, preferably a plurality of biodegradable guiding fibres, wherein least a majority of the guiding
25 means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_0 required for establishing regenerated contact between the ends of an injured nerve using the device for said regeneration.

This means that the in vivo degradation time t_1 is
30 selected such as when the guiding means, preferably in the form of fibres, by degradation (and/or dissolution) becomes essentially disintegrated, they will provide no substantial axon growth guiding function and no substantial axon growth blocking effect.

35 Said first device according to the invention may alternatively be described as a device for promoting a process of regeneration of an injured nerve, said process

presenting a pre-contact period extending from applica-
tion of the device at the injured nerve up to a first oc-
currence of a re-established (regenerated) contact be-
tween the ends of the injured nerve, and post-contact pe-
5 riod extending from the end of the pre-contact period and
up to the end of the regeneration process, wherein said
device comprises a nerve encasement structure and a plu-
rality of guiding means, preferably fibres, which present
an in vivo biodegradability being such that at least a
10 majority of said guiding means becomes essentially disin-
tegrated by degradation (and/or dissolution) during the
pre-contact period.

It shall be noted that the in vivo degradation time
 t_1 generally is a distribution of a plurality of in vivo
15 degradation times, such as t_{1a} , t_{1b} , t_{1c} , t_{1d} , etc, all of
which fulfil the requirements of t_1 .

Also the in vivo degradation time t_2 is generally a
distribution of a plurality of in vivo degradation times,
such as t_{2a} , t_{2b} , t_{2c} , t_{2d} , etc, all of which fulfil the re-
20 quirements of t_2 .

It shall also be noted that the term "nerve encase-
ment structure" means a structure that at least partly
encases the ends of the injured nerve.

The device according to the invention for promoting
25 regeneration of an injured nerve may also be referred to
as a nerve regeneration device.

The term "approximately" is in this context defined
as about $\pm 20\%$, preferably about $\pm 10\%$.

Furthermore, the nerve encasement structure is pref-
30 erably in the form of a tubular structure, such as a con-
duit.

Preferably, substantially all of the guiding means
present an in vivo degradation time t_1 being less than or
approximately equal to the time t_c required for estab-
35 lishing contact between the ends of an injured nerve us-
ing the device for said regeneration.

+46 31630263

Ink. t. Patent- och reg.verket

2003 -07- 0 3

Muvudföreläsaren Karsen

13

The in vivo degradation time t_1 is preferably less than the time t_c required for establishing regenerated contact between the ends of an injured nerve using the device for said regeneration.

5 Fig 1 shows a sectional schematic drawing of an embodiment of the device 1 according to the invention. The device 1 comprises a biodegradable nerve encasement structure 2 having a plurality of biodegradable guiding means in the form of fibres 3 within its lumen. The nerve
10 encasement structure 2 encases the proximal and distal ends 4 and 5, respectively, of the injured nerve. The lumen of the nerve encasement structure 2 preferably comprises a hydrogel 6 having nerve growth promoting substances and/or cells 7 dispersed therein (described in
15 more detail in the following text).

Preferably, at least a major part of the nerve encasement structure present an in vivo degradation time (t_2) being longer than the in vivo degradation time of the majority of the guiding means (t_1). Thus, the major-
20 ity of the guiding means are in vivo preferably degraded faster than the major part of the nerve encasement structure.

In other words, at least a major part of the nerve encasement structure will not become disintegrated during
25 the pre-contact period. Said major part of the nerve encasement structure becomes disintegrated during the post-contact period or afterwards. The approximate time (t_c) required for establishing contact between the ends of an injured nerve using the device according to the invention
30 is expressed by Formula I:

$$\frac{L}{v} \leq t_c \leq 14 + \left(\frac{L}{v} \right) \quad (I)$$

wherein

35 L = gap size [mm]
 v = axon growth rate [mm/day]

+46 31630263

Ink. t. Patent- och reg.verket

2003 -07- 0 3

Huvudföreläsning Kassen

14

As stated above, the axon growth rate is generally about 1 mm/day, but the rate may vary within the range of from about 0.5 to about 2 mm/day.

The time period t_e is calculated from the date of surgery (not the date of injury). Thus, the time t_e according to Formula I depends on when the device is placed in vivo, i.e. how long time after nerve injury surgery occurs. If for instance surgery occurs on the same day as the injury, t_e is about $[14 + (L/v)]$. That is, the nerve will be paralysed for about 14 days before the regeneration process starts. However, it shall be noted that even if surgery occurs some days, such as 10 days, after injury, t_e may in some cases still be about $[14 + (L/v)]$ since surgery may affect the lag period.

The approximate time (t_r) required for the entire nerve regeneration process to occur using the device according to the invention is expressed by Formula II:

$$2 \times \left(\frac{L}{v} \right) \leq t_r \leq 14 + 2 \times \left(\frac{L}{v} \right) \quad (\text{II})$$

20

The time period t_r is calculated from the date of surgery (not the date of injury). Thus, the time t_r according to Formula II depends on when the device is placed in vivo, i.e. how long time after nerve injury surgery occurs. If for instance surgery occurs on the same day as the injury, t_r is about $[14 + 2 \times (L/v)]$. That is, the nerve will be paralysed for about 14 days before the nerve regeneration process starts. However, it shall be noted that even if surgery occurs some days, such as 10 days, after injury, t_r may in some cases still be about $[14 + 2 \times (L/v)]$ since surgery may affect the lag period.

As stated above, the nerve encasement structure should advantageously support the fragile growing nerve even after the regeneration process has established contact between the nerve ends, and said supporting structure should preferably last approximately (about $\pm 20\%$)

+46 31630263

Ink. t. Patent- och reg.verket

2003 -07- 0 3

Huvudfaxen Kassar

15

at least until the entire nerve regeneration process has been completed.

Table 1 shows preferred approximate in vivo degradation times of the guiding means, preferably in the form of fibres, and the encasement structure, respectively, for varying nerve gap sizes and axon growth rates calculated using formulas (I) and (II), under proviso that surgery occurs on the date of injury.

It shall be noted that the time periods, t_1 and t_2 , given in Table 1 are only approximate and shall only be interpreted as indicative of suitable in vivo degradation times according to the invention.

Table 1

15

Gap size [mm]	0.5 mm/day		1 mm/day		2 mm/day	
	t_1 [days]	t_2 [days]	t_1 [days]	t_2 [days]	t_1 [days]	t_2 [days]
5	24±5	≥(34±7)	19±4	≥(24±5)	17±3	≥(19±4)
10	34±7	≥(54±11)	24±5	≥(34±7)	19±4	≥(24±5)
50	114±23	≥(214±43)	64±13	≥(114±23)	39±8	≥(64±13)
100	214±43	≥(414±83)	114±23	≥(214±43)	64±13	≥(114±23)
200	414±83	≥(814±163)	214±43	≥(414±83)	114±23	≥(214±43)

The second device according to the invention for promoting regeneration of an injured nerve comprising a biodegradable nerve encasement structure, and a plurality of biodegradable guiding means, preferably a plurality of biodegradable fibres, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 , at least a major part of the nerve encasement structure presents an in vivo degradation time t_2 , and t_2 being longer than t_1 ($t_2 > t_1$).

The in vivo degradation time t_1 of said at least a majority of the guiding means of the second device according to the invention is preferably less than or approximately equal to a time t_0 required for establishing

+46 31630263

Ink. t. Patent- och reg.verket

2003 -07- 0 3

Huvudfaxen Kassen

16

regenerated contact between the ends of an injured nerve using the device for said regeneration.

The nerve regeneration (first and second) device according to the invention may be used for healing of both short (defined in rats as essentially no gap to a gap < 10 mm) and long (defined in rats as ≥ 10 mm) nerve gaps. The (first and second) device according to the invention may be used for healing of nerve injuries, such as nerve gaps within the range of from 1 mm to 20 cm or even longer, in mammals, including man.

The (first and second) device according to the invention is particularly useful for healing of long nerve gaps.

The nerve encasement structure is preferably porous to allow passage of substances essential for nerve cell metabolism, such as water, salts, nutrients, nerve growth promoting substances, etc.

The (first and second) device according to the invention may be used either for nerve healing in the PNS or in the CNS, such as injuries of the spinal cord.

The material of the nerve encasement structure and the material of the guiding means should preferably each comprise one or more biodegradable polymers. The material of the nerve encasement structure and the material of the guiding means may either comprise the same type of biodegradable polymer(s) or different types of biodegradable polymers.

Examples of biodegradable polymers include biocompatible and biodegradable polyesters; polyorthoesters; polyphosphoesters; polycaprolactam; polyvinyl alcohols; polyanhydrides; polyesteramides; polyamides; polyurethanes; polydioxanes; polyacetals; polyketals; polycarbonates; polyorthocarbonates; polyphosphazenes; polyalkylene oxalates; polyalkylene succinates; poly(amino acids) (i.e. polypeptides or proteins) ; polyethers, polysaccharides (e.g. alginate); and copolymers, terpolymers or combinations or mixtures thereof.

+46 31630263

Ink. t. Patent- och reg.verket

2003 -07- 0 3

Huvudfaxen Kassar

17

Biodegradable polyesters include homo- and copolymers of hydroxycarboxylic acids, such as glycolic acids, lactic acids (D-, L- or DL-form), hydroxybutyric acid, hydroxyvaleric acid, trimethyl carbonate, dioxane, and caprolactone.

Examples of biodegradable homo- and copolymers of hydroxycarboxylic acids are polyglycolic acids (also called polyglycolides) (PGA); polylactic acids (also called polylactides) (PLA); polylactic-co-glycolic acids (PLGA); polymalic acids; polyhydroxybutyrate (also called polyhydroxybutyric acid) (PHB); polyhydroxyvalerate (also called polyhydroxyvaleric acid) (PHV); poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV); polytrimethyl carbonates; polydioxanes, such as poly(p-dioxanone) (PDS); and polycaprolactones, such as poly(ϵ -caprolactone) (PCL).

In vivo, the polyesters of hydroxycarboxylic acids undergo random non-enzymatic hydrolysis of backbone ester linkages (bulk degradation) into bioresorbable metabolites. During hydrolysis of the hydrocarboxylic acid polymers, oligomers and/or monomers having carboxylic groups are formed.

The guiding means, preferably a plurality of guiding fibres, and the nerve encasement structure according to the invention are most preferably made of a material comprising PHB (e.g. poly-3-hydroxybutyrate (P3HB) or poly-4-hydroxybutyrate (P4HB)).

Use of PHB in nerve healing has been found to be advantageous since PHB is biocompatible, biodegradable, non-toxic, non-carcinogenic, and non-antigenic and corresponds well to the desired mechanical properties of a nerve healing material, such as strength, flexibility, elasticity, and processability. The biodegradation pattern of PHB also makes the polymer well suited for use in nerve healing.

The in vivo degradation time for a biodegradable polymer, such as PHB, may be adjusted by altering the mo-

2003-07-03

Huvudfrågan Kassen

18

lecular weight of the polymer, e.g. by subjecting the polymer to heat or radiation, or by chemical modification of the polymer.

As known to persons skilled in the art, a biodegradable polymer having a lower molecular weight is in vivo degraded faster than a polymer having a higher molecular weight.

Thus, said one or more polymers comprised in the material of the guiding means preferably present an average molecular weight which is lower than an average molecular weight of said one or more polymers comprised in the material of the nerve encasement structure.

The material of the nerve encasement structure and the material of the guiding means, preferably fibres, according to the invention preferably each comprises PHB having an average molecular weight (M_w) within the range of from 10 000 to 1 000 000 g/mol, more preferably from 50 000 to 500 000 g/mol, under proviso that the average molecular weight of the guiding means is preferably lower than the molecular weight of the nerve encasement structure.

When used in surgical procedures, the nerve encasement structure and the guiding means should exhibit certain mechanical properties, such as strength and flexibility. The structure and the guiding means should also be easy to handle and should preserve their integrity (until a disintegrated state has been reached by degradation and/or dissolution). Moreover, the structure and the guiding means should have a certain biodegradability. Therefore, the PHB material preferably has a molecular weight of at least 50 000 g/mol. Furthermore, even though no negative effect is observed when a porous nerve encasement structure encompasses a regenerated nerve, there is no need for the device to last longer than necessary in the body of the patient. Thus, the molecular weight of the PHB material is preferably equal to

or below 1 000 000 g/mol, more preferably equal to or below 500 000 g/mol.

It shall also be noted that in some cases, physicians might consider it advantageous that the device is in an essentially disintegrated state when the nerve regeneration process has been finalized, i.e. at approximate ($\pm 20\%$) t_r days after surgery. As a consequence, the molecular weight of the biodegradable polymer of the nerve encasement structure may be selected in accordance with the gap size of the injured nerve. Since a shorter nerve gap is bridged and regenerated faster than a longer gap, a polymer having a lower molecular weight and thus a shorter degradation time may be selected for the healing of a shorter nerve gap in comparison to the healing of a longer nerve gap.

The (first and second) device according to the invention preferably comprises a nerve encasement structure of a material comprising PHB having an average molecular weight within the range of from 100 000 to 250 000 g/mol, and guiding means, preferably fibres, of a material comprising PHB having an average molecular weight within the range of from 50 000 to < 250 000 g/mol, under proviso that the molecular weight of the PHB of the guiding means is lower than the molecular weight of the PHB of the nerve encasement structure.

A preferred embodiment of the (first and second) device according to the invention includes a nerve encasement structure comprising a compressed non-woven sheet of biodegradable fibres, preferably PHB fibres, having an essentially unidirectional fibre orientation. Said sheet is preferably formed into a tubular structure during in vivo application thereof and said fibre orientation is then oriented along the longitudinal axis of the tubular structure. The sheet is in vivo preferably kept in the form of a tubular structure by use of for instance a glue, such as a fibrin glue, sutures through the sheet, or frictional engagement.

Preferably, the non-woven sheet, forming a nerve encasement structure in vivo, has a thickness within the range of 0.1-0.4 mm, more preferably 0.2-0.3 mm.

Moreover, the non-woven sheet preferably has a weight per
5 unit area within the range of 9-11 mg/cm².

The plurality of guiding means, preferably fibres, more preferably PHB fibres, may be in the form of individual guiding means, such as individual fibres (monofilaments) and/or a guiding means matrix, such as a fibre
10 matrix.

A preferred embodiment of the (first and second) device according to the invention includes a plurality of biodegradable guiding fibres, preferably PHB fibres, in the form of non-woven, preferably non-compressed, having
15 an essentially unidirectional fibre orientation, which in use is oriented along the direction of desired nerve growth.

The guiding fibres preferably have a cross-sectional dimension $\leq 50 \mu\text{m}$.

The (first and second) device according to the invention advantageously further comprises a hydrogel matrix, preferably within the lumen of the nerve encasement structure. The guiding means, preferably fibres, may be dispersed, preferably homogeneously, in the hydrogel matrix.
20
25

Examples of hydrogel materials include agarose; alginate; chitosan; collagen; laminin; cross-linked polyethylene oxide; cross-linked hyaluronic acid; and polyvinylalcohol.

It shall be noted that the hydrogel material may be in a dehydrated state when applied in vivo. The material is in that case hydrated in vivo by body fluids thus forming a hydrogel. Alternatively, the dehydrated hydrogel material may be hydrated in situ, by for instance the
30
35 physician performing the surgery, prior to application in vivo.

It may also be advantageous to comprise one or more biologically active substances or cells, such as a nerve growth promoting substance selected from the group consisting of nerve growth factor (NGF); brain-derived neurotrophic factor (BDNF); neurotrophin-3 (NT-3); neurotrophin-4 (NT-4); glial growth factor (GGF); insulin-like growth factor (IGF); platelet-derived growth factor (PDGF); fibroblast growth factor (FGF); transforming growth factor (TGF); epidermal growth factor (EGF); endothelial cells; fibroblasts; Schwann cells; olfactory ensheathing cells (a type of glial cells), stem cells or precursor cells thereof, in the (first and second) device according to the invention.

The invention also relates to a first kit for preparing the above described first device according to the invention for promoting regeneration of an injured nerve. Said first kit comprises a sheet, preferably biodegradable, and a plurality of biodegradable guiding means, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_0 required for establishing regenerated contact between the ends of an injured nerve using the device for said regeneration.

The invention also relates to a second kit for preparing the above described second device according to the invention for promoting regeneration of an injured nerve. Said second kit comprises a biodegradable sheet and a plurality of biodegradable guiding means, wherein at least a majority of the guiding means presents an in vivo degradation times t_1 , at least a major part of the sheet presents an in vivo degradation time t_2 , and t_2 being longer than t_1 ($t_2 > t_1$).

The sheet is when used surgically formed into a nerve encasement structure, preferably in the form of a tubular structure, such as a conduit.

2003 -07- 0 3

Huvudfakern Kessan

22

It shall be noted that the (first and second) kit may comprise a sheet already formed into a tubular structure (sheet in tubular form).

5 The considerations and preferred embodiments of the (first and second) kit are analogous to the considerations and preferred embodiments described above in relation to the (first and second) device according to the invention.

10 As described above, it may be advantageous to further comprise a hydrogel matrix within the lumen of the nerve encasement structure. Thus, the (first and second) kit according to the invention may advantageously comprise a hydrogel material, preferably a hydrogel material in a dehydrated state.

15 A hydrogel may be applied onto the sheet, and then dehydrated. Thus, the sheet comprised in the (first and second) kit according to the invention may comprise a coating of a dehydrated hydrogel material.

20 The (first and second) kit may further advantageously comprise distilled water for hydration of the dehydrated hydrogel material.

Furthermore, the (first and second) kit may also advantageously comprise one or more biologically active substances or cells, such as a nerve growth promoting substance selected from the group consisting of nerve growth factor (NGF); brain-derived neurotrophic factor (BDNF); neurotrophin-3 (NT-3); neurotrophin-4 (NT-4); glial growth factor (GGF); insulin-like growth factor (IGF); platelet-derived growth factor (PDGF); fibroblast growth factor (FGF); transforming growth factor (TGF); epidermal growth factor (EGF); endothelial cells; fibroblasts; Schwann cells; olfactory ensheathing cells; stem cells or precursor cells thereof.

30 An example of a method of manufacturing the (first or second) device according to the invention using the (first or second) kit according to the invention comprises:

2003 -07- 0 3

Muvudfaxen Kassen

23

- dispersing (in vitro) the plurality of biodegradable guiding means, preferably a plurality of fibres, in a hydrogel (before or after hydration thereof),
- applying the hydrogel and the guiding means on at least a part of at least one surface of the sheet (in this embodiment, the hydrogel comprises dispersed guiding means),
- dehydrating the hydrogel-coated sheet, and
- forming (preferably in vivo) the coated sheet into a nerve encasement structure, preferably a tubular structure, wherein said coating faces the lumen of the nerve encasement structure.

In this case, a kit comprising a sheet, biodegradable guiding means, preferably in the form of fibres, and a dehydrated hydrogel material is integrally formed as an implantable body.

Thus, the invention also relates to a first biodegradable sheet for preparing the first device according to the invention for promoting regeneration of an injured nerve, said sheet having at least one surface at least partly coated with a dehydrated hydrogel material and a plurality of biodegradable guiding means, preferably in the form of fibres, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_2 required for establishing regenerated contact between the ends of an injured nerve using device.

The invention also relates to a second biodegradable sheet for preparing the second device according to the invention for promoting regeneration of an injured nerve, said sheet having at least one surface at least partly coated with a dehydrated hydrogel material and a plurality of biodegradable guiding means, preferably in the form of fibres, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 , at least a major part of the sheet presents an in vivo degradation time t_2 , and t_2 being longer than t_1 ($t_2 > t_1$).

Said dehydrated hydrogel material of the above disclosed (first and second) biodegradable sheet according to the invention may also advantageously comprise one or more of the above mentioned biologically active substances or cells. The (first or second) kit or the (first or second) biodegradable sheet according to the invention may be used to produce the (first or second) device according to the invention.

The (first or second) kit or the (first or second) biodegradable sheet according to the invention may also be used in a method for repairing an injured nerve. Such a method comprises at least partly encasing the ends of the injured nerve and the plurality of guiding means, preferably fibres, using the sheet preferably formed into a tubular structure, such as a conduit.

Thus, the invention also relates to a method for promoting regeneration of an injured nerve comprising the step of applying at said injured nerve the (first or second) device according to the invention.

The invention also relates to the use of biodegradable guiding means, preferably in the form of fibres, for promoting regeneration of an injured nerve, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_c required for establishing regenerated contact between the ends of an injured nerve using the guiding means for said regeneration.

The guiding means are preferably made from a material comprising one or more biodegradable polymers, more preferably a biodegradable polyester, such as PHB.

The average molecular weight of said PHB is preferably within the range of from 50 000 to 250 000 g/mol.

The plurality of guiding means may be in the form of individual guiding means, such as individual fibres, and/or a guiding means matrix, such as a fibre matrix.

2003 -07- 0 3

Huvudfaxen Kassen

25

The guiding means are preferably fibres in the form of a fibre matrix, such as non-woven having an essentially unidirectional fibre orientation.

While the invention has been described in detail and
5 with reference to specific embodiments thereof, it will
be apparent for one skilled in the art that various
changes and modifications can be made therein without de-
parting from the spirit and scope thereof.

10

Figure 1

+46 31630263

Ink. t. Patent- och reg.verket

7703 -07- 0 3

26

Huvudtaxen Kassen

CLAIMS

1. A device for promoting regeneration of an injured nerve comprising a nerve encasement structure and a plurality of biodegradable guiding means characterized in that at least a majority of the guiding means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_0 required for establishing regenerated contact between the ends of an injured nerve using the device for said regeneration.

2. A device according to claim 1, wherein the in vivo degradation time t_1 being less than the time t_0 required for establishing regenerated contact between the ends of an injured nerve using the device for said regeneration.

3. A device according to any one of the preceding claims, wherein at least a major part of the nerve encasement structure presents an in vivo degradation time t_2 being longer than t_1 ($t_2 > t_1$).

4. A device for promoting regeneration of an injured nerve comprising a biodegradable nerve encasement structure, and a plurality of biodegradable guiding means, characterized in that at least a majority of the guiding means presents an in vivo degradation time t_1 , at least a major part of the nerve encasement structure presents an in vivo degradation time t_2 , and t_2 being longer than t_1 ($t_2 > t_1$).

5. A device according to any one of the preceding claims, wherein the plurality of biodegradable guiding means are a plurality of biodegradable guiding fibres.

6. A device according to any one of the preceding claims, wherein the material of the nerve encasement structure and the material of the guiding means each comprises one or more biodegradable polymers.

5

7. A device according to claim 6, wherein said one or more biodegradable polymers comprises one or more biodegradable polyesters.

10

8. A device according to claim 7, wherein said one or more biodegradable polyesters comprises PHB.

15

9. A device according to any one of claims 6-8, wherein said one or more polymers comprised in the material of the guiding means present an average molecular weight which is lower than an average molecular weight of said one or more polymers comprised in the material of the nerve encasement structure.

20

10. A nerve regeneration device according to claim 9, wherein the material of the nerve encasement structure and the material of the guiding means each comprises PHB having an average molecular weight within the range of from 50 000 to 500 000 g/mol.

25

11. A device according to claim 10, wherein the PHB average molecular weight of the nerve encasement structure is within the range of from 100 000 to 250 000 g/mol and the PHB average molecular weight of the guiding means is within the range of from 50 000 to < 250 000 g/mol.

30

12. A device according to any one of the preceding claims, wherein the nerve encasement structure comprises a compressed non-woven sheet of biodegradable fibres having an essentially unidirectional fibre orientation.

35

13. A device according to any one of the preceding claims, wherein the plurality of guiding means are biodegradable fibres in the form of non-woven having an essentially unidirectional fibre orientation.

5

14. A device according to any one of the preceding claims, further comprising a hydrogel matrix.

15 10 15. A device according to any one of the preceding claims, further comprising one or more biologically active substances or cells.

16. A device according to claim 15, wherein said one or more biologically active substances comprises a nerve growth promoting substance selected from the group consisting nerve growth factor (NGF); brain-derived neurotrophic factor (BDNF); neurotrophin-3 (NT-3); neurotrophin-4 (NT-4); glial growth factor (GGF); insulin-like growth factor (IGF); platelet-derived growth factor (PDGF); fibroblast growth factor (FGF); transforming growth factor (TGF); and epidermal growth factor (EGF).

17. A device according to claim 15, wherein said one or more biologically active cells is selected from the group consisting of endothelial cells; fibroblasts; Schwann cells; olfactory ensheathing cells; stem cells or precursor cells thereof.

18. A kit for preparing a device for promoting regeneration of an injured nerve, said kit comprising a sheet and a plurality of biodegradable guiding means, characterized in that at least a majority of the guiding means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_2 required for establishing regenerated contact between the ends of an injured nerve using the device for said regeneration.

2003-07-03

Huvudfaxen Kansen

29

19. A kit according to claim 18, wherein the in vivo degradation time t_1 being less than the time t_c required for establishing regenerated contact between the ends of an injured nerve using the device for said regeneration.

5

20. A kit according to claim 18 or claim 19, wherein the sheet presents an in vivo degradation time t_2 being longer than t_1 ($t_2 > t_1$).

10 21. A kit for preparing a device for promoting regeneration of an injured nerve, said kit comprising a biodegradable sheet and a plurality of biodegradable guiding means, characterized in that at least a majority of the guiding means presents an in vivo
15 degradation times t_1 , at least a major part of the sheet presents an in vivo degradation time t_2 , and t_2 being longer than t_1 ($t_2 > t_1$).

22. A kit according to any one of claims 18-21,
20 wherein the plurality of biodegradable guiding means are a plurality of biodegradable guiding fibres.

23. A kit according to any one of claims 18-22,
wherein the material of the sheet and the material of the
25 guiding means each comprises one or more biodegradable polymers.

24. A kit according to claim 23, wherein said one or more biodegradable polymer comprises one or more biodegradable polyester.
30

25. A kit according to claim 24, wherein said one or more biodegradable polyester comprises PHE.

35 26. A kit according to any one of claims 23-25, wherein said one or more polymers comprised in the material of the guiding means present an average molecular

30

weight which is lower than an average molecular weight of said one or more polymers comprised in the material of the sheet.

5 27. A kit according to claim 26, wherein the material of the and the material of the guiding means each comprises PHB having an average molecular weight within the range of from 50 000 to 500 000 g/mol.

10 28. A kit according to claim 27, wherein the PHB molecular weight of the sheet is within the range of from 100 000 to 250 000 g/mol and the PHB molecular weight of the guiding means is within the range of from 50 000 to < 250 000 g/mol.

15 29. A kit according to any one of claims 18-28, wherein the sheet comprises a compressed non-woven sheet of biodegradable fibres having an essentially unidirectional fibre orientation.

20 30. A kit according to any one of claims 18-29, wherein the plurality of guiding means are biodegradable fibres in the form of non-woven having an essentially unidirectional fibre orientation.

25 31. A kit according to any one of claims 18-30, further comprising a hydrogel material.

30 32. A kit according to claim 31, wherein the hydrogel is in a dehydrated state.

35 33. A kit according to any one of claims 18-32, further comprising one or more biologically active substances or cells.

34. A kit according to claim 33, wherein said one or more biologically active substance comprises a nerve

+46 31630263

Ink. t. Patent- och reg.verket

2003 -07- 0 3

31

Muvudfaxen Kasean

growth promoting substance selected from the group consisting of nerve growth factor (NGF); brain-derived neurotrophic factor (BDNF); neurotrophin-3 (NT-3); neurotrophin-4 (NT-4); glial growth factor (GGF); insulin-like growth factor (IGF); platelet-derived growth factor (PDGF); fibroblast growth factor (FGF); transforming growth factor (TGF); and epidermal growth factor (EGF).

35. A kit according to claim 33, wherein said one or more biologically active cells is selected from the group consisting of endothelial cells; fibroblasts; Schwann cells; olfactory ensheathing cells; stem cells or precursor cells thereof.

36. A biodegradable sheet for preparing a device for promoting regeneration of an injured nerve, characterized in having at least one surface at least partly coated with a dehydrated hydrogel material and a plurality of biodegradable guiding means, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_c required for establishing regenerated contact between the ends of an injured nerve using device.

25

37. A biodegradable sheet for preparing a device for promoting regeneration of an injured nerve, characterized in having at least one surface at least partly coated with a dehydrated hydrogel material and a plurality of biodegradable guiding means, wherein at least a majority of the guiding means presents an in vivo degradation time t_1 , at least a major part of the sheet presents an in vivo degradation time t_2 , and t_2 being longer than t_1 ($t_2 > t_1$).

35

+46 31630263

Ink t Patent- och reg.

2003 -07- 03

32

Huvudföreläsning Kungälv

38. A biodegradable sheet according to claim 36 or claim 37, wherein the plurality of biodegradable guiding means are a plurality of biodegradable guiding fibres.

5 39. A biodegradable sheet according to any one of claims 36-38, said dehydrated hydrogel material further comprising one or more biologically active substances or cells.

10 40. Use of a plurality of biodegradable guiding means for promoting regeneration of an injured nerve, characterized in that at least a majority of the guiding means presents an in vivo degradation time t_1 being less than or approximately equal to a time t_0 required for establishing regenerated contact between the
15 ends of an injured nerve using the guiding means for said regeneration.

20 41. Use according to claim 40, wherein the plurality of biodegradable guiding means are a plurality of biodegradable guiding fibres.

25 42. Use according to claim 40 or claim 41, wherein the material of the guiding means comprises one or more biodegradable polymers.

30 43. Use according to claim 42, wherein said one or more biodegradable polymer comprises one or more biodegradable polyesters.

44. Use according to claim 43, wherein said one or more biodegradable polyesters comprises PHB.

35 45. Use according to claim 44, wherein PHB has an average molecular weight within the range of from 50 000 to 250 000 g/mol.

2003 -07- 0 3

Huvudfaxen Kassar

33

46. Use according to any one of claims 40-45,
wherein the guiding means are fibres in the form of non-
woven having an essentially unidirectional fibre orienta-
tion.

5

47. A method for promoting regeneration of an in-
jured nerve c h a r a c t e r i z e d in comprising the
step of applying at said injured nerve a device according
to any one of claims 1-18.

10

A

9
4
5
0
0
0
0

Abstract

The invention relates to promotion of a process for regeneration of an injured nerve using a plurality of guiding means, preferably a plurality of guiding fibres, presenting an in vivo biodegradability being such that at least a majority of said guiding means becomes essentially disintegrated by degradation (and/or dissolution) during a pre-contact period extending from application of the device at the injured nerve up to a first occurrence of a re-established (regenerated) contact between the ends of the injured nerve. During a post-contact period extending from the end of the pre-contact period and up to the end of the regeneration process, the disintegrated guiding means will provide no substantial axon growth guiding function and no substantial axon growth blocking effect.

20

25

30

Figure elected for publication: Fig 1

1/1

Ink. t. Patent- och reg.verket

2003 -07- 0 3

Huvudfönern Kassen




Fig. 1

030703 1436 FAX +46 31630263

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.